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June 20081186 Go et alof a routine 6-month CT in the follow-up of most EVAR
patients is safe because it does not identify any significant
clinical findings. Further study of alternative surveillance
modalities and the natural history of late EVAR compli-
cations may identify safer, less frequent follow-up regi-
mens for some subgroups of EVAR patients.
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Dr Hasan Dosluoglu (Buffalo, NY). In my practice, I have
omitted the 1-month scan altogether if I am happy with the
completion angiogram at the end of the procedure, because the
studies show that most of these type 2 endoleaks, especially, will go
away in 6months. So why can’t we do the exact reverse of what you
did, and omit the first month CT and get the first one at 6 months
and maybe go from there?
Dr Michael R. Go. Probably the most important reason to
obtain the 1-month computed tomography (CT) is the 11% of
patients who, in our hands, have an abnormality on that scan
after EVAR. Almost all had no abnormalities on their comple-
tion angiograms. In fact, there were five type 1 endoleaks and
one type 3 endoleak noted on 1-month scans in our study, all of
which would require immediate intervention by today’s stan-
dards.
Dr Keith Calligaro, (Philadelphia, Pa). A comment and a
question. I think that in your last slide, the conclusion should be
that a CT scan is not necessary at 6 months for Ancure grafts. The
vast majority of your grafts were Ancure, and the remaining
numbers were so small, I don’t know if you can make that conclu-
sion about those other type of grafts. My question is whether you
are still doing CT scans as follow-up? We’ve stopped doing routine
CT scans and just do duplex scan surveillance. If the first CT scan
is normal, we will follow up with duplex scans only, unless aDr Go. There were a significant number of patients who did
not have Ancure grafts, 63% in group I. But you are right, that
number was only 26% in group II. And as we find out more and
more that EVAR outcomes, and probably complications, are
device-specific, your point is well taken. The frequency of positive
findings at 1 month is equivalent, which would allow us to extend
the recommendations to all grafts. As you mention, we agree that
duplex can be substituted for CT once the aneurysm fails to
expand; this requires a couple of CT scans and does not apply
necessarily to the first year of follow-up, which is the focus of this
paper. Our current policy is similar to yours.
Dr Clifford Buckley (Temple, Tex). We have come to the
same conclusion. We have reviewed 4-year follow-up of 424 pa-
tients between our own institution and the UT Southwestern in
Dallas, using a combined database. The distribution of the grafts
was fairly equal between all of the four major players—Cook,
Medtronic, Gore, and Ancure. The number of abnormal findings
in patients who had one normal CT scan was extremely low. The
number of interventions that were required was extremely low. It
made us look at whether we were gaining anything at all from the
intensity of the follow-up. It appears that we gained very little.
Most of the patients who required an intervention came for an
unscheduled evaluation with new symptoms. If they had aneurysm
sac enlargement, they came in with complaints of abdominal pain
or back pain. People who had graft limb occlusions came in
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yielded very little information affecting patient care.
Dr Go. That is similar to our findings here. However, our
current data only apply to the first year of follow-up and cannot be
extrapolated to late follow-up, where a small number of patients
still present with asymptomatic findings requiring treatment.
Dr Mark Fillinger (Lebanon, NH). I appreciate your paper
and it was a nice study. I think I agree with your conclusions, but
I just wanted to sound a couple notes of caution. One was your
conclusion that the 6-month was of no value, period. But actually
what you showed was there was no value if you had a normal
1-month CT, which was the majority of the patients.
The other caution is using “no change in diameter” as your
criteria for “no problems.” If you look at the Gore Pivotal Clinical
trial, the vast majority of patients had no enlargement at 1 year by
diameter, and yet we now know that over a third of them were
already enlarging by volume at that point. So you have to be
cautious about using an insensitive parameter to declare that there
is no present or future problem.
Dr Go.We agree that the 6-month CT is of little significance
only when the 1-month CT is normal. Since a 1-year CT is still in
our algorithm and we use a significant change of 5 mm in diameter
as our threshold, we do not see the utility of a more sensitive
longitudinal parameter.
Dr Roger Greenhalgh (London, United Kingdom). I
thought the paper was a very useful contribution, and the infor-
mation given us about the 6-month CT scan is a very helpful piece
in the jigsaw. I think it is important to put this into perspective. We
have gone through an era of the trials and during this decade of the
trials, we have had to adopt a very, very careful attitude to this then
new technique. CT scan was the agreed method of checking and
during the trial period, we got used to using CT scans, frequently
at first and annually.I think we are moving away from the early experience, and it
then becomes relevant to look at different health systems in the
different parts of the world. The issue that you do not have in the
United States to the same extent as in certain parts of Europe and
Scandinavia and Britain with their National Health Service is this
irritating matter of cost-effectiveness. Cost-effectiveness is some-
thing that our governments and the authorities will take into
account and they will measure the benefit of EVAR against the
various drawbacks against that benefit. One of the most important
costs is the CT scan. An annual CT scan would seem to be high
priority to lose in the follow-up for cost-effectiveness to have any
hope of success. That is the background for my question.
But my question is, can you examine your data to look and see
if you could, in retrospect, have done without your annual, 1-year
CT scan? Could you have used other modalities to find those issues
reliably without CT scan? Because if you can, that will be the
beginning of a potential cost-effective future for EVAR.
Dr Go. Certainly, any advantage of EVAR over open repair in
terms of cost-effectiveness is abrogated in the long-term by the
need for this ongoing surveillance. Thus, we have been moving
toward ultrasound surveillance. It would be possible to reanalyze
our database beyond 1 year, and this is one of the next steps in our
ongoing effort at University of Pittsburgh to pare down the
surveillance regimen.
Dr Alan B. Lumsden (Houston, Tex). I think one of the
exciting opportunities in imaging is that all of the new systems
which we’re installing will do fluoro-CT. We are going to have the
opportunity in an operating room after the anticoagulation is
reversed to do our ownCT scans. And the question then is, wemay
not need a follow-up CT scan for 2 or 3 years, but it is going to put
CT scanning in the operating room, basically, under a certain
semblance of control of the surgeons.
